AI assistant
Sending…
Altimmune, Inc. — Director's Dealing 2021
Jun 3, 2021
33207_dirs_2021-06-02_a9c5e5dc-eb53-4d77-bded-de59573dc44b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2021-05-30
Reporting Person: Garg Vipin K (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-30 | Common Stock, par value $0.0001 | F | 2577 | $12.65 | Disposed | 304606 | Direct |
Footnotes
F1: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of restricted stock.
More from Altimmune, Inc.
Share Issue/Capital Change
2026
May 13
Regulatory Filings
2026
May 13
Capital/Financing Update
2026
Apr 22
Declaration of Voting Results & Voting Rights Announcements
2026
Apr 16
Major Shareholding Notification
2026
Mar 26
Annual Report
2026
Mar 17
Proxy Solicitation & Information Statement
2026
Mar 17
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 27
Regulatory Filings
2026
Feb 6